Editas Medicine Inc
Research Editas Medicine Inc (EDIT) on Bullrun: market cap USD 313.30M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerEDIT
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 313.30M
- Financial periodFY2025
- RevenueUSD 40.52M
- Revenue growth25.4%
- Net income-USD 160.06M
- Free cash flow-USD 165.85M
Valuation Snapshot
latest market cap is USD 313.30M.
About Editas Medicine Inc
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia;
Frequently asked questions
What is Editas Medicine Inc's market cap?
Editas Medicine Inc's market capitalization is USD 313.30M.
What does Editas Medicine Inc do?
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology.